{"id":"NCT05540522","sponsor":"Pfizer","briefTitle":"A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older","officialTitle":"A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-09-12","primaryCompletion":"2024-03-12","completion":"2024-03-12","firstPosted":"2022-09-14","resultsPosted":"2025-05-08","lastUpdate":"2025-05-08"},"enrollment":45789,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza, Human"],"interventions":[{"type":"BIOLOGICAL","name":"Quadrivalent influenza modRNA vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Quadrivalent influenza vaccine","otherNames":[]}],"arms":[{"label":"Quadrivalent influenza modRNA vaccine, 18 through 64 years of age","type":"EXPERIMENTAL"},{"label":"Quadrivalent influenza vaccine, 18 through 64 years of age","type":"ACTIVE_COMPARATOR"},{"label":"Quadrivalent influenza modRNA vaccine, ≥65 years of age","type":"EXPERIMENTAL"},{"label":"Quadrivalent influenza vaccine, ≥65 years of age","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza vaccine in healthy adults 18 years of age and older.","primaryOutcome":{"measure":"Percentage of Participants Reporting First Episode of LCI Cases With Associated Per-Protocol ILI Caused by Any Strain at Least 14 Days After Vaccination: 18-64 Years","timeFrame":"Day 15 to surveillance cut-off (approximately 6 months)","effectByArm":[{"arm":"qIRV: 18-64 Years","deltaMin":0.63,"sd":null},{"arm":"Licensed QIV: 18-64 Years","deltaMin":0.95,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":321,"countries":["United States","Argentina","Chile","New Zealand","Philippines","South Africa"]},"refs":{"pmids":[],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=C4781004"]},"adverseEventsSummary":{"seriousAny":{"events":83,"n":9191},"commonTop":["Injection site pain (PAIN)","Fatigue (FATIGUE)","Headache (HEADACHE)","Myalgia (MUSCLE PAIN)","Chills (CHILLS)"]}}